These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9595388)

  • 1. Differential inhibition of wild-type endothelin-converting enzyme-1 and its mutants.
    Savage P; De Lombaert S; Shimada K; Tanzawa K; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S16-8. PubMed ID: 9595388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.
    Shetty SS; Savage P; DelGrande D; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S68-70. PubMed ID: 9595403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
    Fink CA; Moskal M; Firooznia F; Hoyer D; Symonsbergen D; Wei D; Qiao Y; Savage P; Beil ME; Trapani AJ; Jeng AY
    Bioorg Med Chem Lett; 2000 Sep; 10(17):2037-9. PubMed ID: 10987444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
    Jeng AY; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Trapani AJ
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S36-9. PubMed ID: 11078330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH.
    Fahnoe DC; Knapp J; Johnson GD; Ahn K
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S22-5. PubMed ID: 11078325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutagenesis of Glu403 to Cys in rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked homodimer: analogy with endothelin-converting enzyme.
    Hoang MV; Sansom CE; Turner AJ
    Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):925-9. PubMed ID: 9581575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of metalloprotease inhibitors on smooth muscle endothelin-converting enzyme activity.
    Balwierczak JL; Kukkola PJ; Savage P; Jeng AY
    Biochem Pharmacol; 1995 Jan; 49(3):291-6. PubMed ID: 7857315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1.
    Takayanagi R; Liu W; Ito T; Ohnaka K; Nawata H
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S62-3. PubMed ID: 9595401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modelling and site-directed mutagenesis of the active site of endothelin-converting enzyme.
    Sansom CE; Hoang MV; Turner AJ
    Protein Eng; 1998 Dec; 11(12):1235-41. PubMed ID: 9930673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble human endothelin-converting enzyme-1: expression, purification, and demonstration of pronounced pH sensitivity.
    Ahn K; Herman SB; Fahnoe DC
    Arch Biochem Biophys; 1998 Nov; 359(2):258-68. PubMed ID: 9808768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
    Yap EY; Battistini B; McKay KO
    Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells.
    Azarani A; Boileau G; Crine P
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):439-48. PubMed ID: 9657986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11.
    Shimada K; Takahashi M; Turner AJ; Tanzawa K
    Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):863-7. PubMed ID: 8645169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid and selective endothelin-converting enzyme assay: characterization of a phosphoramidon-sensitive enzyme from guinea pig lung membrane.
    Fawzi AB; Cleven RM; Wright DL
    Anal Biochem; 1994 Nov; 222(2):342-50. PubMed ID: 7864357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor.
    Feldman DL; Mogelesky TC; Chou M; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S342-5. PubMed ID: 11078415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.